Physician profile
Roberta T Lee
NPI 1518054261
$6,180.15
in general payments reported to CMS, 2019-2025
30 companies · $826 in 2025
The $826 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $587 · 2021: $876 · 2022: $1,038 · 2023: $852 · 2024: $660 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,306.28 | 2019-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $520.29 | 2019-2025 | Vaxelis, Vaxneuvance, Rotateq |
| Glaxosmithkline, LLC. | $495.17 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $480.00 | 2019-2025 | |
| Neos Therapeutics, LP | $350.86 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $345.79 | 2020-2025 | Elaprase |
| Cranial Technologies, INC | $323.07 | 2019-2025 | Doc Band |
| Corium, LLC | $287.06 | 2021-2024 | Azstarys, Azstarys |
| Sobi, INC | $232.59 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $213.67 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $200.57 | 2021-2025 | |
| Shire North American Group INC | $188.22 | 2019 | |
| Edwards Lifesciences Corporation | $188.02 | 2023 | The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Cumberland Pharmaceuticals, INC. | $150.20 | 2019-2025 | Kristalose |
| Kowa Pharmaceuticals America, INC. | $141.56 | 2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $124.03 | 2025 | Nemluvio |
| Adlon Therapeutics L.P. | $119.07 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $111.26 | 2025 | Jornay Pm |
| Genentech USA, INC. | $81.63 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $64.73 | 2025 | Acthar |
| Janssen Pharmaceuticals, INC | $62.50 | 2020 | |
| Supernus Pharmaceuticals, INC. | $46.68 | 2021 | |
| Kyowa Kirin, INC. | $26.82 | 2025 | |
| Arbor Pharmaceuticals, INC. | $23.97 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.54 | 2025 | Alvesco |
| Novartis Pharmaceuticals Corporation | $18.06 | 2019 | |
| Seqirus USA INC | $14.36 | 2022 | |
| Photonicare INC | $14.34 | 2024 | Otosight Middle Ear Scope |
| Phadia US INC. | $14.08 | 2024 | Immunocap |
| Mission Pharmacal Company | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.